Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase

分组1 - Kymera Therapeutics reported a 4Q25 GAAP EPS of -$0.97, missing consensus estimates by approximately $0.18 [1] - Revenue for the quarter was $2.9 million, representing a year-over-year decline of about 60.8%, and also fell short of consensus estimates [1]